Monday, February 17, 2014 - A nationwide leader in product and drug safety litigation, The Onder Law Firm is pleased to announce the launch of the Risperdal Gynecomastia Lawsuit Center. The Onder Law Firm‘s new website offers comprehensive information to the public on Risperdal risks and side effects, and is a clearinghouse for information on Risperdal boys breast growth lawsuits, providing answers to frequently asked questions regarding Risperdal gynecomastia claims.
Johnson & Johnson and the drug giant‘s pharmaceutical subsidiary Janssen have already faced several major Risperdal lawsuits. Notable among these is a $2.2 billion settlement in criminal and civil fines Johnson & Johnson reached with the Department of Justice in November of 2013 for claims the company marketed Risperdal for off-label uses to teens (among others) despite evidence that Risperdal causes an increased risk for gynecomastia (Risperdal Litigation, Philadelphia Court of Common Pleas in Pennsylvania, case number 100300296). The first Risperdal settlement for an individual with male breast growth was reached for a Risperdal lawsuit filed by Aaron Banks (Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January 2010, No. 00618). Banks, who took Risperdal for five years between the ages of 9 and 14, required surgical removal of the breasts he grew while taking Risperdal. Banks‘ lawyer, Stephen Sheller, inferred that the FDA‘s failure to require a Risperdal gynecomastia warning had also contributed to the lack of public awareness on the subject, saying, "Risperdal should be a drug of last resort. The adverse event profile is so significant; you don‘t want to use it except as a last resort. There are many alternatives to these kinds of drugs. But ‘big pharma‘ and the FDA have failed to protect the public."
Gynecomastia is a condition caused by elevated prolactin levels which results in boys and men growing female-type breasts. Gynecomastia can occur for a variety of reasons, both natural and artificial. Anti-psychotic drugs in general, such as Risperdal, are widely known to increase the risk of male breast growth. Research conducted by Duke University indicates that Risperdal leads to the greatest risk for gynecomastia of any drug in this class; in one study conducted in partnership with the FDA, Risperdal was responsible for 70% of cases of gynecomastia. Risperdal breast growth has required surgical removal in some patients, and leads to a variety of long-lasting emotional problems including shame, self-loathing, poor body image, and social isolation.
The Onder Law Firm is currently accepting inquiries from boys, men, and the families of boys and men who have developed male breasts while taking Risperdal. Risperdal lawyers are investigating these inquiries for possible Risperdal boys breast growth lawsuits against Janssen and Johnson & Johnson. The Onder Law Firm has won major settlements for clients in the areas of drug and medical device recalls, as well as product and family safety. The firm is nationally-renowned for its work on window blind strangulation, and is uniquely experienced in fighting for the rights of individuals against powerful corporations. Men, boys, and family members of those individuals who have been diagnosed with gynecomastia and took Risperdal are eligible for a free evaluation with a Risperdal male breast growth attorney, and may contact the firm through its Risperdal Gynecomastia Lawsuit Center website.
The Onder Law Firm also welcomes Risperdal lawsuit inquiries from other law firms, either to handle these inquiries or work as co-counsel.